Literature DB >> 2825353

HTLV-V: a new human retrovirus isolated in a Tac-negative T cell lymphoma/leukemia.

V Manzari1, A Gismondi, G Barillari, S Morrone, A Modesti, L Albonici, L De Marchis, V Fazio, A Gradilone, M Zani.   

Abstract

A new human retrovirus was isolated from a continuous cell line derived from a patient with CD4+ Tac- cutaneous T cell lymphoma/leukemia. This virus is related to but distinct from human T cell leukemia/lymphoma virus types I and II (HTLV-I and HTLV-II) and human immunodeficiency virus (HIV-1). With the use of a fragment of provirus cloned from one patient with T cell leukemia, closely related sequences were found in DNA of the cell line and of tumor cells from seven other patients with the same disease; these sequences were only distantly related to HTLV-I. The phenotype of the cells and the clinical course of the disease were clearly distinguishable from leukemia associated with HTLV-I. All patients and the wife of one patient showed a weak serological cross-reactivity with both HTLV-I and HIV-1 antigens. None of the patients proved to be at any apparent risk for HIV-1 infection. The name proposed for this virus is HTLV-V, and the date indicate that it may be a primary etiological factor in the major group of cutaneous T cell lymphomas/leukemias, including the sporadic lymphomas known as mycoses fungoides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825353     DOI: 10.1126/science.2825353

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  17 in total

1.  Polymerase chain reaction (PCR) amplification demonstrates the absence of human T-cell lymphotrophic virus (HTLV)-I specific pol sequences in peripheral T-cell lymphomas.

Authors:  T Henni; M Divine; P Gaulard; C Haioun; M Duc Dodon; M F Gourdin; L Desforges; M Goossens; F Reyes; J P Farcet
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

Review 2.  Cutaneous lymphoproliferative disorders: strategies for molecular biological analysis and their major findings.

Authors:  G S Wood
Journal:  Springer Semin Immunopathol       Date:  1992

Review 3.  The new dermatology.

Authors:  M W Greaves
Journal:  BMJ       Date:  1990-02-17

4.  Multicenter evaluation of the novel ABN Western blot (immunoblot) system in comparison with an enzyme-linked immunosorbent assay and a different Western blot.

Authors:  B Weber; G Hess; R Enzensberger; F Harms; C J Evans; A Hamann; H W Doerr
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

5.  No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma.

Authors:  G S Wood; J M Schaffer; R Boni; R Dummer; G Burg; M Takeshita; M Kikuchi
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

6.  Antibodies against retroviral core proteins in relation to disease outcome in patients with mycosis fungoides.

Authors:  A Ranki; K M Niemi; P Nieminen; K Krohn
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

7.  Investigation of atypical western blot (immunoblot) reactivity involving core proteins of human immunodeficiency virus type.

Authors:  S L Josephson; N S Swack; M T Ramirez; W J Hausler
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

8.  Detection of HTLV-I proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas.

Authors:  I Anagnostopoulos; M Hummel; P Kaudewitz; H Herbst; O Braun-Falco; H Stein
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

9.  Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides.

Authors:  D Zucker-Franklin; E E Coutavas; M G Rush; D C Zouzias
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

10.  Detection of Epstein-Barr virus genome in primary cutaneous T and B cell lymphomas and pseudolymphomas.

Authors:  K Peris; H Niedermeyer; L Cerroni; T Radaskiewicz; S Chimenti; H Höfler
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.